<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02995850</url>
  </required_header>
  <id_info>
    <org_study_id>4-2016-0252</org_study_id>
    <nct_id>NCT02995850</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis</brief_title>
  <official_title>A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, single-center, phase Ib/II study, evaluating efficacy&#xD;
      and feasibility of cytoreductive surgery(CRS), extensive peritoneal lavage, hyperthermic&#xD;
      intraperitoneal chemotherapy(HIPEC) and post-operative intraperitoneal chemotherapy&#xD;
      combination in gastric cancer with peritoneal metastasis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal metastases in gastric cancer are considered to indicate terminal disease due to&#xD;
      poor prognosis because systemic chemotherapy is unlikely to accumulate in peritoneal nodules&#xD;
      in cytotoxic concentrations. Cytoreductive surgery (CRS) along with hyperthermic&#xD;
      intraperitoneal chemotherapy (HIPEC) has been suggested to improve survival in select&#xD;
      patients with limited peritoneal spread, resulting in a median overall survival (OS) of 8 to&#xD;
      14 months. It remains unclear, however, which regimen is best and who have benefits from CRS&#xD;
      and HIPEC. Herein, we has conducting prospective phase Ib/II trial of CRC and HIPEC with&#xD;
      intraperitoneal paclitaxel and cisplatin, and oral S-1 in gastric cancer with peritoneal&#xD;
      metastasis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ib: Maximum tolerate dose</measure>
    <time_frame>3 months</time_frame>
    <description>Ib: To determine the MTD of orally administered S-1 + intraperitoneal paclitaxel +cisplatin in gastric cancer with peritoneal metastasis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>II: Safety</measure>
    <time_frame>3 months</time_frame>
    <description>II:To assess the safety and tolerability of CRS +HIPEC (Clavien-Dindo classification of surgical complication &amp; NCI-common terminology criteria for adverse events(CTC-AE) for chemotherapy]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>12 months</time_frame>
    <description>the length of time from the patient signing the consent form until the patient is still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Progression-free survival)</measure>
    <time_frame>12 months</time_frame>
    <description>the length of time from the patient signing the consent form until the patient shows disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR (response rate)</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of complete response to partial response These will be estimated by the Kaplan-Meire method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Gastric Cancer With Peritoneal Metastasis (PCI&lt;12)</condition>
  <arm_group>
    <arm_group_label>anti-cancer drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRS+HIPEC</intervention_name>
    <description>Ib&#xD;
Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.&#xD;
II&#xD;
① CRS If PCI &lt;12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.&#xD;
If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI &lt;12, CRS will be done.&#xD;
② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.&#xD;
③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.&#xD;
④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks.</description>
    <arm_group_label>anti-cancer drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient age of 19 years or older and age of 75 years or younger.&#xD;
&#xD;
          2. Histologically proven gastric or esophagogastric junction adenocarcinoma with&#xD;
             peritoneal metastasis under diagnostic laparoscopy.&#xD;
&#xD;
          3. Primary tumor measured as resectable in preoperative images.&#xD;
&#xD;
          4. Performance status based on ECOG : 0~1&#xD;
&#xD;
          5. No prior treatment (chemotherapy, radiotherapy, etc.)&#xD;
&#xD;
          6. Adequate hepatic, renal, and hematologic function&#xD;
&#xD;
               -  ANC≥1,500/uL,&#xD;
&#xD;
               -  hemoglobin≥9.0g/dL&#xD;
&#xD;
               -  platelet≥100,000/uL&#xD;
&#xD;
               -  total Bilirubin: ≤ 1.5 × upper normal limit&#xD;
&#xD;
               -  Creatinine&lt;1.5mg/dL&#xD;
&#xD;
               -  AST/ALT, ALP ≤ 2.5 x upper normal limit&#xD;
&#xD;
          7. Patients who can understand this study and sign the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who has distant metastasis or para-aortic lymph node metastasis or&#xD;
             retroperitoneal metastasis except peritoneal metastasis. (But the patient who has&#xD;
             ovarian metastasis with resectable status can be enrolled.)&#xD;
&#xD;
          2. Primary tumor cannot be resected because of direct invasion to other important organ.&#xD;
             (But, if the invaded organ can be resected together, such as spleen, gallbladder,&#xD;
             distal pancreas, and liver, the patient can be enrolled)&#xD;
&#xD;
          3. HER2 positive patient&#xD;
&#xD;
          4. Patient with active viral infection (for example, HIV, HBV, HCV, except stable status&#xD;
             of HBV infection)&#xD;
&#xD;
          5. Pregnant patient, or patient in breast-feeding, or who is planning pregnancy.&#xD;
&#xD;
          6. Patients in exclusion criteria of TS-1, cisplatin, paclitaxel&#xD;
&#xD;
               -  Patients with a history of severe hypersensitivity to these drugs&#xD;
&#xD;
               -  Patients with severe bone marrow depression&#xD;
&#xD;
               -  patients who has severe hepatic, renal disorder&#xD;
&#xD;
               -  patients who has hereditary problem or galactose intolerance, lapp lactase&#xD;
                  deficiency, or glucose-galactose malabsorption&#xD;
&#xD;
          7. Patients who has important medical problem or infection&#xD;
&#xD;
               -  Cerebrovascular accident(CVA) within 1 year&#xD;
&#xD;
               -  Heart attack within 6 months, uncontrolled hypertension, unstable angina,&#xD;
                  uncontrolled congestive heart failure(CHF), severe arrhythmia&#xD;
&#xD;
               -  Major operation or injury within 28 days&#xD;
&#xD;
               -  Severe and not recovered wound, ulcer, fracture&#xD;
&#xD;
               -  Uncontrolled bleeding disease&#xD;
&#xD;
               -  Recent active gastric infection&#xD;
&#xD;
          8. Patient with another primary cancer within last 5 years&#xD;
&#xD;
          9. Patient on medication which can interact with the drugs used in this study&#xD;
             (fluoropyrimidine-group antineoplastic agents, flucytosine, phenytoin, etc)&#xD;
&#xD;
         10. Patients with other systemic chemotherapy or radiotherapy&#xD;
&#xD;
         11. Patients with psychiatric or neurologic disorder so that he or she cannot understand&#xD;
             and sign the consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Woo Jin Hyung, M.D.</last_name>
    <phone>82-2-2228-2129</phone>
    <email>WJHYUNG@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Surgery, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Woo Jin Hyung, MD</last_name>
      <phone>82-2-2228-2129</phone>
      <email>WJHYUNG@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2016</study_first_posted>
  <last_update_submitted>March 14, 2019</last_update_submitted>
  <last_update_submitted_qc>March 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

